Sermorelin vs Ipamorelin
Clinics offer these two almost interchangeably, often in the same sentence. Their standing with the FDA is not interchangeable at all, and that is the one thing about them that can be checked rather than asserted.
- On the listIpamorelin acetate, named by the FDA as possibly presenting significant safety risks
- Not listedSermorelin does not appear on that list at all
- Once approvedSermorelin held FDA approvals; ipamorelin has never held one
- ZeroTrials comparing the two against each other
The short version
Both are peptides intended to raise the body’s own growth hormone rather than replace it, and both are sold by wellness and anti-ageing clinics. Neither has an approved product on the United States market today. But they are not in the same regulatory position, and the difference is documented.
Ipamorelin acetate appears on the FDA’s list of bulk drug substances that may present significant safety risks when used in compounding. Sermorelin does not appear on that list. That is the substantive difference between them, and it is checkable in a single public document rather than inferred from marketing.
What that difference does not do is establish that either one works, or that sermorelin is safe. It establishes where each stands with the regulator, which is a narrower claim and the only one the evidence supports.
Where each one actually stands
| Sermorelin | Ipamorelin | |
|---|---|---|
| What it is | A GHRH analogue — mimics the signal that tells the pituitary to release growth hormone | A growth hormone secretagogue — acts on a different receptor to prompt the same release |
| Ever FDA-approved? | Yes, twice, both approvals since withdrawn | No, never |
| On the FDA’s safety-risk list for compounding? | No | Yes — ipamorelin acetate, listed 29 September 2023 |
| Approved product available today | None | None |
| Human trial record | Exists, from its approval era | Thin; no approval-grade record |
The row that carries the most weight is the third. The FDA maintains a public list of substances nominated for use in compounding that, in its assessment, may present significant safety risks. Ipamorelin acetate is on it. Sermorelin is not on it, and neither is tesamorelin, the one approved drug in this family.
What “not on the list” means, precisely
Absence from a risk list is not approval, endorsement, or a finding of safety. It means the FDA has not placed that substance in this particular category. Sermorelin still has no approved product, is still supplied compounded, and still carries the uncertainties that come with that. The comparison establishes a difference in standing, not a clean bill of health.
One has a regulatory history, the other has none
Sermorelin was reviewed by the FDA and approved — which means a regulator examined manufacturing, safety and efficacy data and said yes. Those approvals were later withdrawn at the manufacturer’s request, and the FDA has separately indicated the withdrawals were not for reasons of safety or effectiveness. The full account is on our sermorelin page.
Ipamorelin has no equivalent history. It has never been approved for any indication in the United States, so no regulator has ever examined a marketing application for it and agreed. That is not the same as saying it has been rejected — it means the question has never been formally put.
The practical consequence is asymmetric evidence. For sermorelin there is a documented trial record from its approval era, however dated. For ipamorelin, the material in circulation is largely early-stage research and vendor claims, and the FDA’s own listing cites the kind of concerns — including immunogenicity for some routes of administration — that it has raised across this group of peptides.
On the combination clinics tend to sell
Ipamorelin is rarely offered alone. It is usually paired with CJC-1295, on the reasoning that the two act on different receptors and so should combine well.
Worth knowing before evaluating that offer: CJC-1295 is also on the FDA’s safety-risk list, and the concern the agency records against it is the same immunogenicity risk noted for other peptides in this group. So the standard combination is not one listed substance plus a neutral one. It is two listed substances.
We have found no trial evidence that the combination outperforms either component, and no trial comparing it against sermorelin. The rationale for combining them is mechanistic argument rather than demonstrated result, which is a distinction worth holding onto when it is presented as established practice.
What this comparison settles, and what it does not
It settles one thing cleanly: on the FDA’s own documentation these two substances are in different positions, and anyone presenting them as equivalent options is glossing over a difference the agency has recorded in public.
It settles nothing about which produces better results, because no trial has compared them and neither has a current approved product to compare. A difference in regulatory standing is a real and useful signal. It is not a performance result, and it should not be read as one.
What this page will not tell you
- What amount of either to take. Neither has an approved product, both are supplied compounded where they are supplied at all, and concentrations vary by pharmacy. There is no reliable figure to publish and publishing one would be actively unsafe.
- Where to buy either of them. We do not link vendors of unapproved substances, and a listed substance is not something we will help anyone source.
- Which one is more effective. No head-to-head trial exists. Anyone who tells you otherwise is describing an impression, not a result.
- That sermorelin is safe because it is not on the list. Absence from a risk list is not a safety finding, and we will not present it as one.
Sources and method
- The listing itself. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, the FDA’s own page, read on 5 September 2026 and current as of 22 April 2026. Ipamorelin acetate appears there with a listing date of 29 September 2023; CJC-1295 appears with an immunogenicity concern recorded against it. Neither sermorelin nor tesamorelin appears on the page.
- Sermorelin’s approval history. Set out with its sources on our sermorelin page, which covers the two approvals, their withdrawal at the manufacturer’s request, and what the FDA said about the reason.
- What we could not verify. Any comparative trial. We searched for a head-to-head study of sermorelin against ipamorelin and found none, so this page compares regulatory standing and documentation rather than outcomes. We also cannot verify what any individual compounding pharmacy actually supplies, or at what concentration.
- Method. This list changes — substances are added and removed as nominations are reviewed — so the page records the date the list was read and the listing date shown against each entry, rather than treating it as permanent. A claim about regulatory standing is only as current as the document behind it.
Sermorelin overview → Sermorelin vs tesamorelin → Regulatory tracker →
FDA compounding list read 5 September 2026. We recheck this page when that list is revised, since entries are added and removed as nominations are reviewed.